Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.99 |
| ▸ | KIT | P10721 | 11/20 | 0.99 |
| ▸ | LDLR | P01130 | 8/20 | 0.99 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.99 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.99 |
| ▸ | LCK | P06239 | 4/20 | 0.99 |
| ▸ | LYN | P07948 | 4/20 | 0.99 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.99 |
| ▸ | FLT3 | P36888 | 4/20 | 0.99 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | SRC | P12931 | 2/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | CA12 | O43570 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | CA1 | P00915 | 1/20 | 0.99 |
| ▸ | CA2 | P00918 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL1565706 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL31005052 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL434496 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL235245 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL18095566 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL2223849 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1460791 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29392981 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28663798 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301282-B2 | Polymorphic form X of nilotinib dihydrochloride hydrate | CIPLA LIMITED (IN) | 2019-05-28 | — | — | US | claimed |
| US-20180111915-A1 | Novel Polymorphic Form X of Nilotinib Dihydrochloride Hydrate | CIPLA LIMITED (IN) | 2018-04-26 | — | — | US | claimed |
| EP-3271351-A1 | NOVEL POLYMORPHIC FORM X OF NILOTINIB DIHYDROCHLORIDE HYDRATE | Cipla Limited (IN) | 2018-01-24 | — | — | EP | claimed |
| WO-2016151304-A1 | NOVEL POLYMORPHIC FORM X OF NILOTINIB DIHYDROCHLORIDE HYDRATE | CIPLA LIMITED (IN) | 2016-09-29 | — | — | WO | claimed |
| WO-2011033307-A1 | NILOTINIB DIHYDROCHLORIDE SALT | GENERICS [UK] LIMITED (GB) | 2011-03-24 | — | — | WO | claimed |
| CN-113292537-B | Salts of kinase inhibitors and compositions thereof | 汉达癌症医药责任有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116808044-A | Salts of kinase inhibitors and compositions thereof | 汉达癌症医药责任有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230142737-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | HANDA ONCOLOGY, LLC (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115569137-A | Salts of kinase inhibitors and compositions thereof | 汉达癌症医药责任有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115192540-A | Salts of kinase inhibitors and compositions thereof | 汉达癌症医药责任有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-3189045-B1 | NOVEL SALTS OF NILOTINIB AND POLYMORPHS THEREOF | SUN PHARMACEUTICAL IND LTD (IN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113788817-A | Nilotinib semi-hydrochloride monohydrate crystal form and preparation method thereof | 南京海润医药有限公司 | 2021-12-14 | — | — | CN | disclosed |
| US-9090598-B2 | Nilotinib salts and crystalline forms thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-07-28 | — | — | US | disclosed |
| US-20150099885-A1 | Nilotinib Salts And Crystalline Forms Thereof | TEVA PHARMA (IL) | 2015-04-09 | — | — | US | disclosed |
| US-8937082-B2 | Nilotinib salts and crystalline forms thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-01-20 | — | — | US | disclosed |
| US-20130158059-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
| EP-2571863-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011163222-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011033307-A1 | NILOTINIB DIHYDROCHLORIDE SALT | GENERICS [UK] LIMITED (GB) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011033307-A1 | NILOTINIB DIHYDROCHLORIDE SALT | GENERICS [UK] LIMITED (GB) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099885-A1 | Nilotinib Salts And Crystalline Forms Thereof | ABL1, TP53, NRAS | ABL1 1/4885BCR 24/4885KIT 1401/4885 |
| US-20130158059-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | ABL1, TP53, NRAS | ABL1 1/4885BCR 24/4885KIT 1401/4885 |
| US-20180111915-A1 | Novel Polymorphic Form X of Nilotinib Dihydrochloride Hydrate | ABL1, TP53, HLA-DRB1 | ABL1 1/4885BCR 9/4885KIT 559/4885 |
| US-20230142737-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | BRAF, MAP3K21, MAP3K20 | ABL1 30/4885BCR 875/4885KIT 666/4885 |
| US-10301282-B2 | Polymorphic form X of nilotinib dihydrochloride hydrate | ABL1, TP53, HLA-DRB1 | ABL1 1/4885BCR 20/4885KIT 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.